drugset / Trial / NCT06242067
Second-line Treatment of Metastatic Colorectal Cancer
Phase 2
Recruiting
50 enrolled
Qilu Hospital of Shandong University
Binzhou Medical University · collabBinzhou People's Hospital · collabLinyi Tumour Hospital · collabQianfoshan Hospital · collabShandong Provincial Hospital · collabThe Affiliated Hospital of Qingdao University · collabYantai Yuhuangding Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of recurrence.
Timeline
- Start
- 2023-04-23
- Primary completion
- 2024-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | — |
| Subject | Trifluridine/tipiracil | Unknown | 30 mg/m2 | — |